Bender Robert & Associates Trims Stake in Johnson & Johnson $JNJ

Bender Robert & Associates reduced its position in shares of Johnson & Johnson (NYSE:JNJ) by 3.9% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 3,552 shares of the company’s stock after selling 146 shares during the quarter. Bender Robert & Associates’ holdings in Johnson & Johnson were worth $543,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of JNJ. GFG Capital LLC purchased a new position in Johnson & Johnson during the 2nd quarter worth $35,000. Highline Wealth Partners LLC boosted its position in Johnson & Johnson by 51.8% during the 1st quarter. Highline Wealth Partners LLC now owns 252 shares of the company’s stock valued at $42,000 after acquiring an additional 86 shares in the last quarter. Stone House Investment Management LLC bought a new stake in Johnson & Johnson during the 1st quarter valued at $47,000. 1248 Management LLC bought a new stake in Johnson & Johnson during the 1st quarter valued at $48,000. Finally, von Borstel & Associates Inc. bought a new stake in Johnson & Johnson during the 1st quarter valued at $49,000. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Johnson & Johnson

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the firm’s stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the sale, the executive vice president directly owned 178,013 shares in the company, valued at approximately $31,652,491.53. This trade represents a 24.08% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 0.16% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have issued reports on JNJ. Piper Sandler reaffirmed an “overweight” rating on shares of Johnson & Johnson in a research report on Thursday, July 17th. Barclays raised their price objective on Johnson & Johnson from $165.00 to $176.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 17th. JPMorgan Chase & Co. raised their price objective on Johnson & Johnson from $185.00 to $200.00 and gave the stock a “neutral” rating in a research report on Tuesday, September 16th. Citigroup lifted their price target on Johnson & Johnson from $200.00 to $213.00 and gave the stock a “buy” rating in a research report on Tuesday, October 7th. Finally, UBS Group set a $198.00 price target on Johnson & Johnson in a research report on Friday, October 3rd. Two investment analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and eight have issued a Hold rating to the stock. According to MarketBeat.com, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and an average target price of $192.94.

Johnson & Johnson Stock Down 0.2%

Johnson & Johnson stock opened at $190.66 on Monday. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $192.10. The stock’s fifty day simple moving average is $178.48 and its 200-day simple moving average is $163.78. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. The firm has a market capitalization of $459.16 billion, a P/E ratio of 20.39, a P/E/G ratio of 2.40 and a beta of 0.40.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The firm had revenue of $24.02 billion for the quarter. As a group, equities analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th were paid a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 2.7%. The ex-dividend date of this dividend was Tuesday, August 26th. Johnson & Johnson’s payout ratio is presently 55.61%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.